Abstract
The aim of this study was to evaluate fluorine-18 fluorodeoxyglucose positron emission tomography ([18F]FDG PET) as a tool for the differential diagnosis of pancreatic carcinoma while taking into account serum glucose level. A group of 106 patients with unclear pancreatic masses were recruited for the study. PET was performed following intravenous administration of an average of 190 MBq [18F]FDG. Focally increased glucose utilisation was used as the criterion of malignancy. In addition, the \ldstandardised uptake value\rd (SUV) was determined 45 min after injection. Carcinoma of the pancreas was demonstrated histologically in 74 cases, and chronic pancreatitis in 32 cases. Employing visual evaluation, 63 of the 74 (85%) pancreatic carcinomas were identified by PET. In 27 of the 32 cases (84%) of chronic pancreatitis il was possible to exclude malignancy. False-negative results (n=11) were obtained mostly in patients with raised serum glucose levels (10 out of 11), and false-positives (n=5) in patients with inflammatory processes of the pancreas. Thus PET showed an overall sensitivity of 85%, a specificity of 84%, a negative predictive value of 71%, and a positive predictive value of 93%. In a subgroup of patients with normal serum glucose levels (n=72), the results were 98%, 84%, 96% and 93%, respectively. Quantitative assessment yielded a mean SUV of 6.4\+-3.6 for pancreatic carcinoma as against a value of 3.6\+-1.7 for chronic pancreatitis (P\s<0.001), without increasing the diagnostic accuracy. This shows PET to be of value in assessing unclear pancreatic masses. The diagnostic accuracy of PET examinations is very dependent on serum glucose levels.
This is a preview of subscription content, log in via an institution to check access.
References
Bakkevold KE, Arnesjo B, Kambestad B. Carcinoma of the pancreas and papilla of Vater — assessment of resectability and factors influencing resectability in stage I carcinomas. A prospective multicentre trial in 472 patients.Eur J Surg Oncol 1992; 18: 494–507.
DelMaschio A, Vanzulli A, Sironi S, Castrucci M, Mellone R, Staudacher C, Carlucci M, Zerbi A, Parolini D, Faravelli A, Cantaboni A, Garancini P, Di Carlo V. Pancreatic cancer versus chronic pancreatitis: diagnosis with Ca 19-9 assessment, US, CT, and CT-guided fine needle biopsy.Radiology 1991; 178: 95–99.
Bryde-Andersen H, Efferson H, Tjalve E, Burcharth F. CT for assessment of pancreatic and periampullary cancer.Acta Radiol 1993; 34: 569–572.
Inokuma T, Tamaki N, Torizuka T, Fujita T, Magata Y, Yonekura Y, Ohshio G, Imamura M, Konishi J. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluordeoxyglucose: comparison with CT and US.Radiology 1995; 195: 345–352.
Kato T, Hiroshi F, Ito K, Tadokoro M, Ota T, Ikeda M, Isomura T, Ito S, Nishino M, Ishigaki T. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem.Eur J Nucl Med 1995; 22: 32–39.
Stollfuss JC, Glatting G, Friess H, Kocher F, Beger HG, Reske SN. 2-(fluorine-18)-fluoro-2-deoxy-d-glucose PET in detection of pancreatic cancer: value of quantitative image Interpretation.Radiology 1995; 195: 339–344.
Bares R, Klever P, Hauptmann S, Hellwig D, Fass J, Cremerius U, Schumpelick V, Mittermeyer C, Buell U. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.Radiology 1994; 192: 79–86.
Bares R, Dohmen BM, Cremerius U, Faß J, Teusch M, Büll U. Ergebnisse der Positronenemmissionstomographie mit Fluor-18-markierter Fluordeoxyglucose bei Differentialdiagnose und Staging des Pankreaskarzinoms.Radiologe 1996; 36: 435–440.
Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T, Foidart-Willems J. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.Eur J Nucl Med 1996; 23: 1641–1674.
Warburg W.The metabolism of tumors. New York: RR Smith; 1931: 129–169.
Brown RS, Wahl RL. Overexpression of glut-1 glucose transporter in human breast cancer.Cancer 1993; 72: 2979–2985.
Wahl RL, Henry CA, Ethier SP. Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-glucose in rodents with mammary carcinoma.Radiology 1992; 183: 643–647.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zimny, M., Bares, R., Faß, J. et al. Fluorine-18 fluorodeoxyglucose positron mission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 24, 678–682 (1997). https://doi.org/10.1007/BF00841409
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00841409